Terns Pharma unveils positive interim output in Phase 1 TERN-201 trial
Outputs from single ascending dose specify that TERN-201 is well tolerated and generally safe & can inhibit plasma SSAO activity. This trial has now transitioned onto the next level; multiple-ascending dose phase. Terns Pharmaceuticals, Inc., an international biopharmaceutical company aimed at developing and discovering innovative therapies to treat cancer and non-alcoholic steatohepatitis (NASH), reportedly announced interim outputs of, currently under progress, clinical trial of TERN-201, an inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), being made for NASH treatment. Interim data of first clinical study of TERN-201 tells that single, oral TERN-201 administrations were well handled with no important safety findings or any adverse events experienced that would lead to discontinuation. Every dose level studied showed reduction from baseline in SSAO activity of plasma that was maintained up to a week after the single dose TERN-201 administration. Study has now transitioned to multiple dose phase based on these outputs. Chief Medical Officer of Terns, Erin Quirk, M.D. stated that the data seen till date from the clinical study in Phase 1 of TERN-201 has been encouraging and showed that TERN-201 is capable of being a therapy to treat liver fibrosis and NASH. Terns has further advanced two compounds into clinical development this year with TERN-101, a FXR agonist, and Tern-201 in current studies. Quirk added that the company looks forward to check further outcomes from Phase 1 studies of TERN-201 and TERN-101 in this year as the company progresses towards its goal of unveiling effective and safe combination treatments for NASH. Initially, TERN-201 was developed and discovered by Eli Lilly & Company. Terns made a global exclusive deal with Eli Lilly last year to manufacture, develop and commercialize TERN-201 for treating NASH. In Vienna, at International Liver CongressTM 2019, Terns presented preclinical information expressing that TERN-201 enhances NAFLD Activity Score (NAS) & fibrosis in rodent subjects of NASH. Credit Source: https://www.ternspharma.com/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201